Celera's revenues were driven by sales of its KIF6 testing service, but the firm posted a loss for the second quarter in a row on higher SG&A spending related to building its infrastructure following its split from Applera.
Life Technologies, Max Planck Institute for Evolutionary Anthropology, 454 Life Sciences, Applied Biosystems, Baylor College of Medicine, University of Bristol, University of Liverpool, John Innes Centre, Helicos BioSciences, Febit, and more…
Despite increasing evidence that the action of some drugs is influenced by patient genetics, testing for such variants has not been widely adopted as part of standard practice, AAAS meeting attendees heard this weekend.
The molecular diagnostics firm's decline in sales to clinical partners and biothreat customers was the primary cause of its expected decrease in Q4 revenues. It also announced a series of measures aimed at reining in costs in 2009.